Clinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors
Immunotherapy has become the major breakthrough and the most promising treatment, with the host of development of tumor biology, molecular biology and immunology. We have developed anti-ROBO1 CAR-NK cells that can target tumor cells highly expressing ROBO1. The purpose of this study is to evaluate the safety and effectiveness of cell therapy using ROBO1 CAR-NK cells to treat solid tumors.
100 Clinical Results associated with Asclepius Technology Company Group (Suzhou) Co., Ltd.
0 Patents (Medical) associated with Asclepius Technology Company Group (Suzhou) Co., Ltd.
100 Deals associated with Asclepius Technology Company Group (Suzhou) Co., Ltd.
100 Translational Medicine associated with Asclepius Technology Company Group (Suzhou) Co., Ltd.